Recursion needs ‘definitive wins’ to validate platform, says JPMorgan

Following Recursion’s presentation at a Q&A session at the firm’s healthcare conference, JPMorgan said the company’s updates were “largely in line/as anticipated.” The analyst, who continues to believe it will take definitive clinical wins from Recursion’s pipeline to validate the platform and “for shares to become constructive by extension,” maintains a Neutral ratring on the stock.